Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc

Sponsor
Yongtao Han (Other)
Overall Status
Completed
CT.gov ID
NCT05604664
Collaborator
(none)
1,727
1
5.3
324.5

Study Details

Study Description

Brief Summary

The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question[s] it aims to answer is:

  • provide a basis for accurate staging and the relationship between OS and lymph node dissection
Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1727 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Esophageal Squamous Cell Carcinoma
    Actual Study Start Date :
    May 1, 2022
    Actual Primary Completion Date :
    Oct 1, 2022
    Actual Study Completion Date :
    Oct 10, 2022

    Outcome Measures

    Primary Outcome Measures

    1. 5-year survival rate of lymph nodes metastases (%) in patients [2010.1.1-2017.12.30]

      Surgical data were retrospectively collected

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Pathologic findings proved ESCC (8th AJCC/UICC stage T1b-4aN0-3M0)

    2. Underwent esophagecomy (two-field or three-field LN dissection)

    3. The primary tumor was thoracic ESCC

    Exclusion Criteria:
    1. Located outside the thoracic

    2. Patients underwent salvage or R1/R2 esophagecomy

    3. The number of resected lymph nodes (RLNs) less than 15

    4. With neoadjuvant therapy(NT) or salvage chemoradiotherapy(SCRT)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sichuan Cancer Hospital and Research Institute Chengdu Sichuan China 610041

    Sponsors and Collaborators

    • Yongtao Han

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yongtao Han, Clinical Professor, Sichuan Cancer Hospital and Research Institute
    ClinicalTrials.gov Identifier:
    NCT05604664
    Other Study ID Numbers:
    • SCCH-TS2203
    First Posted:
    Nov 3, 2022
    Last Update Posted:
    Nov 4, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Nov 4, 2022